CPhI to Hold Key Conference on the Commercialisation of Biosimilars

BANGALORE, India, September 21, 2012 /PRNewswire/ --

Speed-to-market is one of the key concerns for any biosimilar company looking for expansion. By 2015, sales of biosimilars are expected to reach between USD 1.9 to 2.6 billion. To be part of this tidal growth it is important to tactically analyse markets to develop win-win strategies for market entry, profitable pricing and concrete marketing mediums for commercialisation of biosimilars.

Against this backdrop, CPhI India is launching Commercialisation of Biosimilars 2012, a strategic initiative focusing on the most critical issues pertaining to biosimilars commercialisation in different markets. This event will take place from 1-2 November at The Chancery Pavilion in Bangalore, India and will provide speedy market entry strategies, effective licensing agreements, profitable pricing models, successful marketing and branding strategies and access to key markets like US, UK, China and LATAM.

Commercialisation of Biosimilars 2012 has on board eminent speakers such as Alan Sheppard, Principal Thought Leadership, Global Generics, IMS Health; Orlando Vitor Silva, Head Corporate Affairs, Merck Brazil; Tetsuya Takada, President, TIPharms & Company Japan; Allan Riting Liu, Vice President/Senior Advisor, Wanbang Biopharmaceutical Group China; Purnima Sharma, Chief Executive Officer, Biotech Consortium India Limited (BCIL); Subir Basak, President - Global Drug Discovery Services, Jubilant Life Sciences; Ranjan Chakravarti, Senior Vice President Global Strategy, Ranbaxy and Purvish M Parikh, President, Indian Society of Medical & Pediatric Oncology among other industry experts, all of whom are at the centre stage of the development of effective commercialisation strategies globally.

This event will bring together Heads of Business Development, Marketing, Licensing and Strategy from Biopharmaceutical Manufacturers. This initiative will help to increase awareness about profitable pricing and latest marketing mediums to effectively enter new markets and ensure profitable strategies. To know more about Commercialisation of Biosimilars 2012, visit http://www.commercialisationofbiosimilars.com/pr.

CPhI is a UBM brand, and is the largest and most important meeting place for the Indian pharma industry. Each year CPhI attracts around 850 exhibitors and 30,000 visitors to the show, providing us with an unrivalled reach to all the key decision makers in the Indian Pharma industry.

UBM is a global live media and B2B communications, marketing service and data provider founded in 1918. We help organisations make connections, communicate their proposition and do business effectively. We enable professional people in more than 40 countries around the world to connect and engage with each other, with the markets they serve and with the information they need to succeed. And we do this by whatever means works best - at live events, through digital media or in publications. Company Size: 6000-6500 employees; Website: http://www.ubm.com/.

For further information please contact:
Ms Asan Bano
CPhI Conferences
+91-(022)-4046-1466
[email protected]

SOURCE CPhI